Intra-Cellular Therapies (ITCI) PT Raised to $98 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Canaccord Genuity analyst Sumant Kulkarni raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $98.00 (from $93.00) while maintaining a Buy rating.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- FirstService Corp (FSV) PT Lowered to $179 at BMO Capital
- AppFolio (APPF) PT Raised to $250 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
